Efficacy of 0.1% Xylometazoline-Hydrochloride Nasal Decongestant Spray in Postoperative Sign/Symptom Relief Following Septoplasty: A Randomized Control Trial.

Objective:This study evaluated the efficacy of 0.1% xylometazoline-hydrochloride nasal decongestant spray compared to 0.9% saline nasal spray in relieving post-septoplasty clinical nasal findings and symptoms. Methods: This triple-blinded randomized-clinical-trial was conducted in 2 tertiary-care hospitals in Karachi-Pakistan. A total of 120 septoplasty patients were recruited from June 20, 2022, to June 20, 2023. Randomly equally-assigned participants received either 0.9% isotonic-saline (control group) or 0.1% xylometazoline-hydrochloride (intervention group) nasal sprays. Participants were instructed to use nasal sprays for 1 week, twice daily, with a 12 hour interval between the 2 doses as a single spray per nostril. Follow-up assessments were conducted on days 3 and 7 after surgery. Postoperative symptoms, nasal-endoscopic findings, adverse-effects, and patient satisfaction were compared using Chi-square test and a P value of <.05 was considered significant. Results: Of 120 participants, 106 were analyzed with 53 participants in each group. By the end of third postoperative day, intervention group exhibited significantly lower rates of self-reported symptoms, including bleeding (7.5%:54.7%), nasal obstruction (3.8%:45.3%), headache (1.9%:30.2%), pain (3.8%:7.5%), as well as clinical nasal findings, including nasal edema (1.9%:58.5%), crusting (11.3%:58.5%), nasal discharge (9.4%:22.6%), and nonhealed scarring (18.9%:58.5%), compared to control group (P value < .001). On the seventh day, intervention group exhibited absence of self-reported symptoms and clinical nasal findings, whereas control group still experienced moderate symptoms (P value < .001). Intervention group had significantly higher patient satisfaction (P value < .001). Conclusions: Xylometazoline spray is highly effective in relieving post-septoplasty clinical nasal findings and symptoms, without adverse effects, indicating potential for wider clinical utilization.Trial Registration: UMIN Clinical-trial-registry: UMIN000052217. (https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059598).

A screen printed methodology optimized by molecular dynamics simulation and Lean Six Sigma for the determination of xylometazoline in the presence of benzalkonium chloride in nasal drops.

A new chemically disposable screen-printed modified electrode with yttrium doped manganese oxide (Mn2O3/Y2O3) nanocomposite at screen printed electrode was mainly constructed to quantify xylometazoline hydrochloride (XMZ). The crystallographic parameters were estimated from the XRD spectrum, suggesting that Mn2O3 of cubic phase with average grain size ∼ 77 nm. The SEM images revealed that Y3+ dopants had improved the surface topology. The findings indicate that morphological features play a vital role in improving the electronic properties of the fabricated electrode. Augmentation of Six Sigma (SS) with molecular dynamics simulation (MD) as a theoretical study was widely adopted to improve the current process as a quality management methodology by measuring the process capability to determine if the process meets the desired specification limits. Process capability is determined through measuring the variability in the process output and comparing these variations with the desired specifications. Also, it assures a robust method specification at a high level of targeted performance and statistical confidence. A greenness assessment procedure utilizing the eco-scale algorism was conducted to prove the greenness of the proposed methodology. Additionally, the proposed sensor presented a high sensitivity over the concentration range (1x10-6-1x10-2 mol L-1) of a detection limit 3.93 × 10-7 mol L-1 with the Nernstian cationic slope of 58.18 ± 0.76 mV decade-1 at 25 ± 1 °C.